Recently Featured

BIO 2026: FDA Leadership Confront Workforce Losses, China Competition in Drug Development

July 11, 2026
SAN DIEGO — The U.S. Food and Drug Administration (FDA) is undergoing a significant cultural and operational transformation amid growing U.S.–China competition in biotechnology. This shift is prompting a reevaluation of regulatory frameworks, particularly concerning rare diseases, and emphasizes the need for integrating patient perspectives into the drug development continuum. These themes were central to…

Eli Lilly’s Obesity Drug Receives Exclusive Compassionate Use Approval

July 11, 2026
Eli Lilly’s promising obesity drug, retatrutide, has garnered attention following its approval for exclusive access under the FDA’s compassionate use program. This development raises critical questions about the criteria for such access and the implications for broader patient populations awaiting treatment options. The decision to allow a single individual to receive this candidate underscores the…

Sen. Cassidy Proposes Bill to Restrict 340B Drug Discount Program

July 10, 2026
WASHINGTON — The chair of the Senate health committee, Sen. Bill Cassidy (R-La.), has introduced legislation aimed at restricting the federal 340B drug discount program, which has been financially advantageous for nonprofit hospitals. This move comes at a time when hospitals are grappling with significant financial pressures, particularly due to recent changes in Medicaid funding.…

Proposed CDC Science Office Could Tighten Political Control at Agency

July 10, 2026
WASHINGTON — Political appointees appear poised to gain more control over information coming out of the Centers for Disease Control and Prevention under a proposal to add a separate science office atop the agency. The new office, called the Executive Advisory, Science, and Operations Unit, would review scientific publications, including Morbidity and Mortality Weekly Report,…

Ongoing Cases